Seeking Alpha

More on CVS Caremark's (CVS) Q4: Revenue in the Retail Pharmacy segment rose 5.1% to $16.3B as...

More on CVS Caremark's (CVS) Q4: Revenue in the Retail Pharmacy segment rose 5.1% to $16.3B as higher traffic more than offset the impact of new generic introductions. An effective tax rate and share count that were lower than anticipated contributed to the EPS beat. The company sees FY13 EPS of $3.86-$4.00, roughly in-line with the consensus estimate of analysts calling for $3.94. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)